Fatty acid synthase (FASN), an enzyme that drives de novo lipogenesis, plays a relevant role in metabolic disorders such as obesity, non-alcoholic fatty liver disease (NAFLD) or type 2 diabetes.

Sagimet Biosciences has announced the progression of its lead candidate, denifanstat, an oral, selective fatty acid synthase ...

Using fermentation, University of Alberta researchers have come up with a way to produce higher amounts of a healthy fatty ...

The presentation will spotlight the company’s lead drug candidate, denifanstat, an oral, once-daily fatty acid synthase (FASN) inhibitor, which has shown promising results in the Phase 2b ...

Fatty acids function both as an energy source and as metabolic signalling molecules and affect many vital processes. This complexity combined with the chemical characteristics of lipids present ...

Expert Rev Cardiovasc Ther. 2008;6(3):391-409. Phosphatidic acid phosphatase/phosphohydrolase (PAP) is an enzyme that catalyzes the conversion of phosphatidic acid to ...

and fatty acids is coupled to the generation of an electrochemical gradient across the inner mitochondrial membrane, which is harnessed by the ATP synthase to drive the formation of ATP.